Honnavalli Yogish Kumar

Dr. Honnavalli Yogish Kumar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
TATenzin Adon
Tenzin Adon
DSDhivya Shanmugarajan
Dhivya Shanmugarajan
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar
The discovery of cyclin-dependent kinases (CDK) and their mechanism in regulating the cell cycle process was considered a game-changer in cancer therapy. Cell cycle arrest and apoptosis were both triggered by their inhibition. The CDK4/6 complex acts as a checkpoint during the cell cycle transition from cell growth (G1) to DNA synthesis (S) phase and its deregulation or overexpression induces abnormal cell proliferation and cancer development. Consequently, targeting CDK4/6 has been proposed as a paradigm shift in the anticancer approach. The design and development of effective CDK4/6 inhibitors are increasingly becoming a promising cancer therapy evident with approved drugs such as palbociclib, ribociclib, and abemaciclib, etc. In this article, we explore the biological importance of CDK4/6 in cancer therapy, the development of resistance to monotherapy, and a short overview of PROTAC (Proteolysis Targeting Chimera), a unique and pioneering technique for degrading CDK4/6 enzymes. Overall, our prime focus is to discuss novel CDK4/6 inhibitors with diverse chemical classes and their correlation with computational studies.

3 March 2025 in ChemistrySelect
Verified
Journal Article
Closed access
SBSanyukta Bhattacharya
Sanyukta Bhattacharya
TATenzin Adon
Tenzin Adon
KDKaren Dsouza
Karen Dsouza
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar

1 September 2023 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
PMPeddaguravagari Mounika
Peddaguravagari Mounika
BGB M Gurupadayya
B M Gurupadayya
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar
BNBannimath Namitha
Bannimath Namitha
The ability to address the cell cycle in cancer therapy brings up new medication development possibilities. Cyclin-dependent kinases are a group of proteins that control the progression of the cell cycle. The CDK/cyclin complexes are activated when specific CDK sites are phosphorylated. Because of their non-selectivity and severe toxicity, most first-generation CDK inhibitors (also known as pan-CDK inhibitors) have not been authorized for clinical usage. Despite this, significant progress has been made in allowing pan-CDK inhibitors to be employed in clinical settings. Pan-CDK inhibitors' toxicity and side effects have been lowered in recent years because of the introduction of combination therapy techniques. As a result of this, pan-CDK inhibitors have regained a lot of clinical potential as a combination therapy approach. The CDK family members have been introduced in this overview, and their important roles in cell cycle control have been discussed. Then, we have described the current state of CDK inhibitor research, with a focus on inhibitors other than CDK4/6. We have mentioned first-generation pan-CDKIs, flavopiridol and roscovitine, as well as second-generation CDKIs, dinaciclib, P276-00, AT7519, TG02, roniciclib, and RGB-286638, based on their research phases, clinical trials, and cancer targeting. CDKIs are CDK4/6, CDK7, CDK9, and CDK12 inhibitors. Finally, we have looked into the efficacy of CDK inhibitors and PD1/PDL1 antibodies when used together, which could lead to the development of a viable cancer treatment strategy

1 June 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
UHUmme Hani
Umme Hani
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar
MBM.Yasmin Begum
M.Yasmin Begum
SYSabina Yasmin
Sabina Yasmin
RORiyaz Ali M Osmani
Riyaz Ali M Osmani
Mohammad Yousuf AnsariMohammad Yousuf Ansari
Mohammad Yousuf Ansari

27 January 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TATenzin Adon
Tenzin Adon
SBSanyukta Bhattacharya
Sanyukta Bhattacharya
SMSubbaRao V. Madhunapantula
SubbaRao V. Madhunapantula
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar

8 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TATenzin Adon
Tenzin Adon
DSDhivya Shanmugarajan
Dhivya Shanmugarajan
HAHissana Ather
Hissana Ather
AMAsif Ansari Shaik Mohammad
Asif Ansari Shaik Mohammad
UHUmme Hani
Umme Hani
HKHonnavalli Yogish Kumar
Honnavalli Yogish Kumar
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example exemestane, anastrozole, letrozole), resistance to treatment eventually occurs through the activation of alternative signaling pathways, thus evading the antiproliferative effects of aromatase inhibitors. One of the evasion pathways is Cylin D-CDK4/6-Rb signaling that promotes tumor proliferation and resistance to aromatase inhibitors. There is significant evidence that the sequential inhibition of both proteins provides therapeutic benefits over the inhibition of one target. The basis of this study objective is the identification of molecules that are likely to inhibit both CDK4/6 and aromatase by computational chemistry techniques, which need further biochemical studies to confirm. Initially, a structure-based pharmacophore model was constructed for each target to screen the sc-PDB database. Consequently, pharmacophore screening and molecular docking were performed to evaluate the potential lead candidates that effectively mapped both of the target pharmacophore models. Considering abemaciclib (CDK4/6 inhibitor) and exemestane (aromatase inhibitor) as reference drugs, four potential virtual hit candidates (1, 2, 3, and 4) were selected based on their fit values and binding interaction after screening a sc-PDB database. Further, molecular dynamics simulation studies solidify the stability of the lead candidate complexes. In addition, ADMET and DFT calculations bolster the lead candidates. Hence, these combined computational approaches will provide a better therapeutic potential for developing CDK4/6-aromatase dual inhibitors for HR+ breast cancer therapy.